Folfox plus Bevacizumab

DRUG2 trials

Sponsors

Canadian Cancer Trials Group, Fudan University

Conditions

ChemotherapyColorectal CancerctDNA

Phase 2

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

CompletedNCT01622543

Canadian Cancer Trials GroupColorectal Cancer

Start: 2012-10-26End: 2018-09-12Updated: 2023-08-23

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

RecruitingNCT07562490

Fudan UniversityChemotherapy, Colorectal Cancer, ctDNA

Start: 2025-04-01End: 2027-12-31Target: 100Updated: 2026-05-01

Related Papers

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

2018-02-0152 citations

IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2016-05-205 citations